These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29857164)

  • 21. Nanoparticles for Cancer Targeting: Current and Future Directions.
    Swain S; Sahu PK; Beg S; Babu SM
    Curr Drug Deliv; 2016; 13(8):1290-1302. PubMed ID: 27411485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Size matters: gold nanoparticles in targeted cancer drug delivery.
    Dreaden EC; Austin LA; Mackey MA; El-Sayed MA
    Ther Deliv; 2012 Apr; 3(4):457-78. PubMed ID: 22834077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. There is no better time than the present: nanotechnology as a disruptive innovation for drug development.
    Oo C; Tsai JC; Kao HD
    Drug Discov Today; 2015 Jun; 20(6):645-7. PubMed ID: 25835226
    [No Abstract]   [Full Text] [Related]  

  • 24. EGF-functionalized lipid-polymer hybrid nanoparticles of 5-fluorouracil and sulforaphane with enhanced bioavailability and anticancer activity against colon carcinoma.
    Li S; Xu Z; Alrobaian M; Afzal O; Kazmi I; Almalki WH; Altamimi ASA; Al-Abbasi FA; Alharbi KS; Altowayan WM; Singh T; Akhter MH; Gupta M; Rahman M; Beg S
    Biotechnol Appl Biochem; 2022 Oct; 69(5):2205-2221. PubMed ID: 34775646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid polymer hybrid as emerging tool in nanocarriers for oral drug delivery.
    Hallan SS; Kaur P; Kaur V; Mishra N; Vaidya B
    Artif Cells Nanomed Biotechnol; 2016; 44(1):334-49. PubMed ID: 25237838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls.
    Nafee N; Forier K; Braeckmans K; Schneider M
    Eur J Pharm Biopharm; 2018 Mar; 124():125-137. PubMed ID: 29291931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.
    Babu A; Templeton AK; Munshi A; Ramesh R
    AAPS PharmSciTech; 2014 Jun; 15(3):709-21. PubMed ID: 24550101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks.
    Zhang RX; Ahmed T; Li LY; Li J; Abbasi AZ; Wu XY
    Nanoscale; 2017 Jan; 9(4):1334-1355. PubMed ID: 27973629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in nanooncology.
    Jain KK
    Technol Cancer Res Treat; 2008 Feb; 7(1):1-13. PubMed ID: 18198919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review.
    Indoria S; Singh V; Hsieh MF
    Int J Pharm; 2020 May; 582():119314. PubMed ID: 32283197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery.
    Koning GA; Krijger GC
    Anticancer Agents Med Chem; 2007 Jul; 7(4):425-40. PubMed ID: 17630918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives.
    Mukherjee A; Waters AK; Kalyan P; Achrol AS; Kesari S; Yenugonda VM
    Int J Nanomedicine; 2019; 14():1937-1952. PubMed ID: 30936695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracellular stability of nanoparticulate drug carriers.
    Liu KC; Yeo Y
    Arch Pharm Res; 2014 Jan; 37(1):16-23. PubMed ID: 24214175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent Patents, Formulation and Characterization of Nanoliposomes.
    Rohilla S; Dureja H
    Recent Pat Drug Deliv Formul; 2015; 9(3):213-24. PubMed ID: 26118425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells.
    Gao J; Li W; Guo Y; Feng SS
    Nanomedicine (Lond); 2016 Dec; 11(24):3261-3282. PubMed ID: 27854161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: A synergistic combination nanotherapy for cervical cancer.
    Li C; Ge X; Wang L
    Biomed Pharmacother; 2017 Feb; 86():628-636. PubMed ID: 28027539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanostructured lipid carriers: Promising drug delivery systems for future clinics.
    Beloqui A; Solinís MÁ; Rodríguez-Gascón A; Almeida AJ; Préat V
    Nanomedicine; 2016 Jan; 12(1):143-61. PubMed ID: 26410277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoparticle-assisted combination therapies for effective cancer treatment.
    Hu CM; Aryal S; Zhang L
    Ther Deliv; 2010 Aug; 1(2):323-34. PubMed ID: 22816135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.